NCT07832123尚未招募2 期
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- progression-free survival at12 months
研究概览
简要总结
The precise positioning of the emerging group of pharmacological inhibitors of mutant IDH enzymes remains to be refined by further studies and defined in national and international guidelines. The present study shall help to close this important knowledge gap when trying to define the role of mutant IDH inhibitors in the treatment algorithms for patients with IDH-mutant WHO grade 3 gliomas.
Safusidenib is a novel, oral, potent, brain penetrant inhibitor of mutant IDH1. It has shown high blood brain barrier penetration in both pre-clinical and clinical studies and demonstrated anti-tumor activity with complete or partial responses.
We aim at demonstrating the efficacy of safusidenib in patients with newly diagnosed IDH1-mutant CNS WHO grade 3 oligodendroglioma and astrocytoma, measured by progression-free survival at12 months.
详细描述
Patients meeting the eligibility criteria will be asked whether they are willing to participate in the study. After the consent has been signed, patients will be enrolled. They will then start treatment with safusidenib, 250 mg BID until disease progression, unacceptable toxicity, withdrawal of consent or at investigator discretion. A brain MRI will be performed every 2 months during the first 6 months and then every 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age ≥18 years.
- •Newly diagnosed and histologically confirmed IDH1-mutant WHO grade 3 glioma, without or with residual disease: astrocytoma IDH1-mutant, or oligodendroglioma, IDH1-mutant and 1p/19q-codeleted, CNS WHO grade
- •IDH1 mutation can be defined by immunohistochemistry or by sequencing. Any location in the central nervous system is permitted.
- •Karnofsky performance status of 70 or more.
- •Adequate hematologic and organ functions.
- •If taking corticosteroids, patients must be on a stable or decreasing dose for the 14 days prior first dose of study drug.
- •Female patients must be either documented not to be Women of Childbearing Potential (WOCBP) or must have a negative pregnancy test within 14 days of starting treatment. Additionally WOCBP must agree to use, from the screening to at least 90 days following the last administration of safusidenib, highly effective contraception methods. Male subjects able to father children must agree to use two acceptable methods of contraception throughout the study and during at least 90 days following the last administration of safusidenib (e.g., condom with spermicidal gel). Double-barrier contraception is required.
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
- •Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
排除标准
- •Inability to undergo brain or spine MRI.
- •Intent to be treated with radiotherapy or alkylating agent chemotherapy.
- •Any investigational antitumor therapy other than those under investigation in this study.
- •Any severe concomitant condition including active and uncontrolled infections or other severe concurrent disease, which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
- •Known hypersensitivity to safusidenib, to any drug with similar chemical structure, or to any other excipient present in the pharmaceutical form of safusidenib.
- •Subjects with a corrected QT interval by Fredericia's formula (QTcF) ≥470 milliseconds (msec) or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
- •Subjects with history of significant cardiac disease within 12 months prior to first dose of study drug.
- •Subjects with known human immunodeficiency virus (HIV) are ineligible unless the following criteria are met: have been receiving effective antiretroviral therapy for at least 4 weeks; viral load <400 copies/mL, CD4+ T-cell (CD4+) counts ≥350 cells/μL, an absence of opportunistic infections for the last 12 months, and participant agrees to be treated with anti-viral therapy for the duration of the study, if indicated.
- •Subjects with acute or reactivated hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •Subjects with known history and/or serological evidence of chronic HBV infection will be included only if the following criteria are met: hepatitis B- deoxyribonucleic acid (DNA) viral load is below the limit of quantification, liver function tests meet inclusion criteria (AST, ALT, ALP, bilirubin), and participant agrees to be treated with anti-viral therapy for the duration of the study, if indicated.
- •Subjects with known history and/or serological evidence of HCV infection will be included only if the following criteria are met: hepatitis C-ribonucleic acid (RNA) viral load is below the limit of quantification, liver function tests meet inclusion criteria (AST, ALT, ALP, bilirubin), and participant agrees to be treated with anti-viral therapy for the duration of the study, if indicated.
- •Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements. Only patients capable of judgment can be enrolled.
- •Pregnancy or intention to become pregnant during the course of the study. WOCBP potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.
- •Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.
- •Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
- •Concurrent malignancies unless the patient has been disease-free without intervention for at least one year.
- •Concurrent use of other anti-cancer treatments or agents other than study medication.
研究组 & 干预措施
Safusidenib arm
Experimental
All participants will receive safusidenib (250 mg BID) until progression or unacceptable toxicity.
干预措施: Safusidenib (Drug)
结局指标
主要结局
progression-free survival at12 months
时间窗: 12 months
progression-free survival at 12 months measured by central review of MRI
次要结局
- Objective response to treatment in patients with measurable disease(24 months)
- Progression-free survival at 24 months(24 months)
- Median progression-free survival(48 months)
- Safety(48 months)
- Seizure control(48 months)
- Quality of life (1)(48 months)
- Quality of life (2)(48 months)
- Neurological status(48 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
Phase IV study of Ivosidenib Based Therapy in Indian Participants with Bile Duct Cancer Cholangiocarcinoma or Blood Cancer Acute Myeloid Leukaemia.Intrahepatic bile duct carcinoma, (2) ICD-10 Condition: C92||Myeloid leukemia,CTRI/2026/04/108147Servier India Private Limited, Mumbai, India20
招募中
2 期
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT07392242Memorial Sloan Kettering Cancer Center45
招募中
2 期
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxNCT07471841Timothy Pardee25
招募中
2 期
Tuvusertib in Astrocytoma With ATRX MutationAstrocytomaNCT07417761Grupo Español de Investigación en Neurooncología56
进行中（未招募）
2 期
Safusidenib 治疗 IDH1 突变型脑胶质瘤的 II 期研究IDH1 突变型脑胶质瘤CTR20253759葆元生物医药科技（杭州）有限公司